Navigation Links
Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
Date:4/13/2009

NEW YORK, April 13 /PRNewswire-FirstCall/ -- A top biotech executive, William Pursley, has agreed to become Chairman of Rx for Africa, Inc.'s (Pink Sheets: RXAF) newly created Business Advisory Board. For 25 years Mr. Pursley has held major executive positions in the biotech industry. In 1985 he joined Genentech, Inc., and was on the marketing team that launched Human Growth Hormone (HGH), one of biotech's first products. It was a huge success. In 1985 Pursley joined Genzyme Corp as VP of Marketing and spearheaded the launch of Ceradase, an Orphan Drug for the treatment of Gaucher's Disease. Only 3,000 people in the US suffer from Gaucher's. Hopes were that the drug would reach $40 million in sales by the third year on the market. It did $120 million in year three. Ceradase has gone on to be Genzyme's biggest seller. It's sales currently exceed $600 million. Genzyme's market cap exceeds $18 billion. Mr. Pursley subsequently became CEO of Osiris Therapeutics, Inc., a leading mesenchymal stem cell company, which recently announced a major corporate alliance with Genzyme.

In 1999, Mr. Pursley joined Transkaryotic Therapeutics as Senior VP of Operations, supervising the European launch of the company's first product, Replagal, an orphan drug for Fabry's disease. The drug took 75% market share in Europe. In 2005, Transkaryotic was sold to Shire Pharmaceuticals for $1.6 billion. He has also achieved great success with reimbursement programs for the drugs he has marketed. "With Ceradase, we were successful in getting insurance companies to reimburse patients up to $350,000 a year for their treatment. Today, in Africa, there are multi-billion dollar funds such as PEPFAR and The Global Fund set up to reimburse companies who distribute drugs for disease such as HIV and malaria. I believe I can help Rx access these funds."

Pursley, who has experience marketing drugs in Africa, sees huge growth ahead for the continent. "Once the global recession lifts, I believe that Rx for Africa has the potential to dominate the sub-Saharan region of Africa, which includes Ethiopia and several neighboring countries with aggregate populations in the hundreds of millions. I believe that I can assist Rx for Africa in the launching of its HIV medications and in helping to identify a continuously updated list of the most current medication regimens to pursue as potential new products.

Mr. Pursley will also lead Rx for Africa's efforts to find US and European partners who will use Rx for Africa's low cost of manufacturing in Ethiopia to their competitive advantage. "When Rx for Africa, Inc.'s wholly-owned subsidiary's manufacturing facilities are approved by the US FDA, it should be relatively easy to find a US marketing partner in the States. Rx's cost of goods are spectacularly low and give it a competitive advantage over even India and China."

Dr. Mulugetta Bezzabeh, Chairman and CEO of Rx for Africa, Inc. commented, "We are excited about working with Mr. Pursley. His background in marketing drugs for HIV-AIDS and other diseases that have a major impact in Africa will give us tremendous insight into our task ahead."

Rx for Africa plans a conference call with investors and analysts on June 1, 2009, when Dr. Bezzabeh and Mr. Pursley will update investors on their efforts.

About Rx for Africa, Inc.

Rx for Africa, Inc. is a public New Jersey corporation, formed in 2007 to invest in companies manufacturing generic pharmaceuticals in Sub-Saharan Africa. Rx Africa (Ethiopia) P.L.C. is a wholly-owned operating subsidiary of Rx for Africa, Inc., with a campus just outside Addis Ababa, Ethiopia, comprising a factory, R&D center and office facilities, currently producing six generic pharmaceutical products. The company sells 100% of its current production through distributors. Shares of Rx for Africa, Inc. common stock are traded under the symbol RXAF.PK on the Pink Sheets.

For more information, visit Rx for Africa, Inc.'s website: http://rxforafrica.com

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


'/>"/>
SOURCE Rx for Africa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Former State Representative Terry Parke Joins Secure Services Corp.
5. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
6. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, & Countrys Top Drug Treatment CEO Barry Karlin to Keynote Palm Beach, FL National Moment Of Change Intervention Conference:
7. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
8. Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care
9. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
10. Nobel Honors 3 Former March of Dimes Prize Recipients
11. Over one-third of former American football players had sexual relations with men, study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses health ... if you will be attacked, but when.” However, he and many others involved highlight ... , Improvements in auditing and monitoring have taken security in health care a very ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... Prophecy concerning this present generation. Yisrayl makes an astounding statement when he says ... He explains that the Bible details the current times so plainly that anyone should ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management ... radiology marketing programs at the annual Building Better Radiology Marketing Programs conference, ... Hotel in Fort Worth, Texas. Nine awards are given out in five categories. They ...
(Date:2/24/2017)... ... 2017 , ... Castle Farms, the celebrated Northern Michigan ... the winning couple announced on Feb. 14, 2017, on Facebook. The free wedding ... A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and Other ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 ... Errichtung einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
Breaking Medicine Technology: